<VariationArchive VariationID="619842" VariationName="NM_000558.5(HBA1):c.237del (p.Asn79fs)" VariationType="Deletion" Accession="VCV000619842" Version="10" RecordType="classified" NumberOfSubmissions="7" NumberOfSubmitters="7" DateLastUpdated="2024-06-23" DateCreated="2019-03-14" MostRecentSubmission="2024-04-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="611275" VariationID="619842">
      <GeneList>
        <Gene Symbol="HBA1" FullName="hemoglobin subunit alpha 1" GeneID="3039" HGNC_ID="HGNC:4823" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="176680" stop="177522" display_start="176680" display_stop="177522" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="226678" stop="227519" display_start="226678" display_stop="227519" Strand="+" />
          </Location>
          <OMIM>141800</OMIM>
        </Gene>
        <Gene Symbol="LOC106804613" FullName="hemoglobin subunit alpha 1 recombination region" GeneID="106804613" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="174618" stop="177541" display_start="174618" display_stop="177541" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000558.5(HBA1):c.237del (p.Asn79fs)</Name>
      <CanonicalSPDI>NC_000016.10:177069:C:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="177070" stop="177070" display_start="177070" display_stop="177070" variantLength="1" positionVCF="177069" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="227069" stop="227069" display_start="227069" display_stop="227069" variantLength="1" positionVCF="227068" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>N79fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.177070del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.177070del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.227069del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.227069del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_000006.1" sequenceAccession="NG_000006" sequenceVersion="1" change="g.37933del">
            <Expression>NG_000006.1:g.37933del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046166.1" sequenceAccession="NG_046166" sequenceVersion="1" change="g.2553del">
            <Expression>NG_046166.1:g.2553del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059186.1" sequenceAccession="NG_059186" sequenceVersion="1" change="g.5420del">
            <Expression>NG_059186.1:g.5420del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000558.5" sequenceAccession="NM_000558" sequenceVersion="5" change="c.237del" MANESelect="true">
            <Expression>NM_000558.5:c.237del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000549.1" sequenceAccession="NP_000549" sequenceVersion="1" change="p.Asn79fs">
            <Expression>NP_000549.1:p.Asn79fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1225" sequenceAccession="LRG_1225">
            <Expression>LRG_1225:g.5420del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1225t1" sequenceAccession="LRG_1225t1">
            <Expression>LRG_1225t1:c.237del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1225p1" sequenceAccession="LRG_1225p1" change="p.Asn79fs">
            <Expression>LRG_1225p1:p.Asn79fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000558.4" sequenceAccession="NM_000558" sequenceVersion="4" change="c.237delC">
            <Expression>NM_000558.4:c.237delC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="141800.0219" DB="OMIM" />
        <XRef Type="rs" ID="767911847" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00003" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00009" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00011" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000558.5(HBA1):c.237del (p.Asn79fs) AND not provided" Accession="RCV000759777" Version="7">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-08-03" SubmissionCount="3">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000558.5(HBA1):c.237del (p.Asn79fs) AND alpha Thalassemia" Accession="RCV002282356" Version="3">
        <ClassifiedConditionList TraitSetID="4863">
          <ClassifiedCondition DB="MedGen" ID="C0002312">alpha Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-02-02" SubmissionCount="2">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000558.5(HBA1):c.237del (p.Asn79fs) AND HBA1-related disorder" Accession="RCV003413547" Version="4">
        <ClassifiedConditionList TraitSetID="91731">
          <ClassifiedCondition>HBA1-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-03-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000558.5(HBA1):c.237del (p.Asn79fs) AND multiple conditions" Accession="RCV002485969" Version="1">
        <ClassifiedConditionList TraitSetID="50896">
          <ClassifiedCondition DB="MedGen" ID="C4693823">Erythrocytosis, familial, 7</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0700299">Heinz body anemia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3161174">Hemoglobin H disease</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C4693798">Methemoglobinemia, alpha type</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0002312">alpha Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-03" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-08-03" NumberOfSubmissions="7" NumberOfSubmitters="7" DateCreated="2019-03-14" MostRecentSubmission="2024-04-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16798638</ID>
        </Citation>
        <DescriptionHistory Dated="2021-11-05">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="50896" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="12136" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ALPHA-THALASSEMIA, HEMOGLOBIN H TYPE</ElementValue>
                <XRef Type="MIM" ID="613978" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HEMOGLOBIN H DISEASE, DELETIONAL</ElementValue>
                <XRef Type="MIM" ID="613978" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hemoglobin H disease</ElementValue>
                <XRef ID="Hemoglobin+H+Disease/3294" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013512" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HBH</ElementValue>
                <XRef Type="MIM" ID="613978" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16829" />
                <XRef ID="16829" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000514598" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500318" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570317" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528544" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521288" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512435" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500397" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529069" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-High-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + High Barts Hb (&gt;20-25% Barts) or FAB3), Alpha (a) Thalassemia: Hb H Disease</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-High-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: High Barts Alpha Thalassemia Screening Result (FAB3; FA + Barts &gt; 20-25%), 2023</CitationText>
              </Citation>
              <XRef ID="93616" DB="Orphanet" />
              <XRef ID="C3161174" DB="MedGen" />
              <XRef ID="MONDO:0013512" DB="MONDO" />
              <XRef Type="MIM" ID="613978" DB="OMIM" />
            </Trait>
            <Trait ID="5228" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Heinz body anemias</ElementValue>
                <XRef ID="Heinz+body+anemias/3265" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Heinz body hemolytic anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Heinz body anemia</ElementValue>
                <XRef ID="HP:0005511" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0007705" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10718" />
                <XRef ID="10718" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="178330" DB="Orphanet" />
              <XRef ID="C0700299" DB="MedGen" />
              <XRef ID="MONDO:0007705" DB="MONDO" />
              <XRef Type="MIM" ID="140700" DB="OMIM" />
              <XRef Type="primary" ID="HP:0005511" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="39991" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Methemoglobinemia, alpha type</ElementValue>
                <XRef ID="MONDO:0020835" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16277" />
                <XRef ID="16277" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="C4693798" DB="MedGen" />
              <XRef ID="MONDO:0020835" DB="MONDO" />
              <XRef Type="MIM" ID="617973" DB="OMIM" />
            </Trait>
            <Trait ID="6489" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">alpha Thalassemia</ElementValue>
                <XRef ID="Alpha-Thalassemia/333" DB="Genetic Alliance" />
                <XRef ID="68913001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">A-Thalassemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha thalassemia spectrum</ElementValue>
                <XRef ID="MONDO:0011399" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="621" />
                <XRef ID="621" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four α-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three α-globin genes; --/-α). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.</Attribute>
                <XRef ID="NBK1435" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301608</ID>
                <ID Source="BookShelf">NBK1435</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <XRef ID="846" DB="Orphanet" />
              <XRef ID="C0002312" DB="MedGen" />
              <XRef ID="MONDO:0011399" DB="MONDO" />
              <XRef Type="MIM" ID="604131" DB="OMIM" />
            </Trait>
            <Trait ID="40029" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ERYTHROCYTOSIS 7</ElementValue>
                <XRef Type="Allelic variant" ID="141800.0145" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0090" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0018" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0169" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141850.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141850.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0098" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0126" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0182" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0087" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0063" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141850.0023" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0144" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0109" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141850.0016" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ERYTHROCYTOSIS, ALPHA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617981" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYTHEMIA, ALPHA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617981" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Erythrocytosis, familial, 7</ElementValue>
                <XRef ID="MONDO:0054802" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ECYT7</ElementValue>
                <XRef Type="MIM" ID="617981" DB="OMIM" />
              </Symbol>
              <XRef ID="C4693823" DB="MedGen" />
              <XRef ID="MONDO:0054802" DB="MONDO" />
              <XRef Type="MIM" ID="617981" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="91731" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="70530" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">HBA1-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">HBA1-related disorder</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
          <TraitSet ID="4863" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6489" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">alpha Thalassemia</ElementValue>
                <XRef ID="Alpha-Thalassemia/333" DB="Genetic Alliance" />
                <XRef ID="68913001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">A-Thalassemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha thalassemia spectrum</ElementValue>
                <XRef ID="MONDO:0011399" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="621" />
                <XRef ID="621" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four α-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three α-globin genes; --/-α). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.</Attribute>
                <XRef ID="NBK1435" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301608</ID>
                <ID Source="BookShelf">NBK1435</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <XRef ID="846" DB="Orphanet" />
              <XRef ID="C0002312" DB="MedGen" />
              <XRef ID="MONDO:0011399" DB="MONDO" />
              <XRef Type="MIM" ID="604131" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="37510" SubmissionDate="2016-07-20" DateLastUpdated="2013-04-04" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="141800.0219_ALPHA-THALASSEMIA" title="HBA1, 1-BP DEL, 354C_ALPHA-THALASSEMIA" />
        <ClinVarAccession Accession="SCV000037510" DateUpdated="2013-04-04" DateCreated="2013-04-04" Type="SCV" Version="1" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2006-01-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a newborn of mixed black and Chinese descent who carried the Southeast Asian alpha-0-thal deletion, Eng et al. (2006) also found a 1-bp deletion of cysteine from codon 78 in exon 2 of the HBA1 gene, resulting in a frameshift and premature termination at codon 83.</Attribute>
              <Citation>
                <ID Source="PubMed">16798638</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA1" />
          </GeneList>
          <Name>HBA1, 1-BP DEL, 354C</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DEL, 354C</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="141800.0219" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">ALPHA-THALASSEMIA</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1739229" SubmissionDate="2018-08-31" DateLastUpdated="2022-01-01" DateCreated="2019-03-14">
        <ClinVarSubmissionID localKey="2840759|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000889341" DateUpdated="2022-01-01" DateCreated="2019-03-14" Type="SCV" Version="2" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-10-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000558.3:c.237del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4481696</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5437908" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000558.5:c.237del|OMIM:140700;604131;613978;617973;617981" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002790900" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000558.5:c.237del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="140700" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604131" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613978" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617973" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617981" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3921846" SubmissionDate="2023-07-12" DateLastUpdated="2023-07-16" DateCreated="2021-11-06">
        <ClinVarSubmissionID localKey="GDXSV:279157" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002004863" DateUpdated="2023-07-16" DateCreated="2021-11-06" Type="SCV" Version="4" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" OrgAbbreviation="GDX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>Has been observed in patients with alpha-thalassemia (Eng et al., 2006; Fjeld et al., 2023); Frameshift variant in the C-terminus predicted to result in protein truncation, as the last 64 amino acids are lost and replaced with 5 incorrect amino acids (HGMD); This variant is associated with the following publications: (PMID: 16798638, 20507641, 36567661, 33887194)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA1" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:772226</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000558.4:c.237del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_202_20230712054202</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_69_20211103203310</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_70_20211110054204</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7698665" SubmissionDate="2023-10-19" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="16259106|HBA1-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004113402" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-03-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBA1 c.237delC variant is predicted to result in a frameshift and premature protein termination (p.Asn79Lysfs*6). This variant was reported in an individual with Alpha Thalassaemia (Eng et al 2006. PubMed ID: 16798638). This variant is reported in 0.053% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-227068-AC-A). Frameshift variants in HBA1 are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000558.4:c.237delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">HBA1-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13915440</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8352566" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="3683898|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004565008" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" OrgAbbreviation="ARUP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-08-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBA1: c.237del; p.Asn79LysfsTer6 variant, (also known as Asn78fs when numbered from the mature protein, rs767911847) is reported in the literature along with –SEA deletion in an individual with Hb Bart’s (Eng 2006). This variant is also reported in ClinVar (Variation ID: 619842) and is found in the African population with an allele frequency of 0.05% (4/7614 alleles) in the Genome Aggregation Database. This variant causes a frameshift by deleting a single nucleotide, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Eng B et al. Three new alpha-thalassemia point mutations ascertained through newborn screening. Hemoglobin. 2006;30(2):149-53. PMID: 16798638.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.227069del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9056506" SubmissionDate="2024-04-19" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey="104765706|Orphanet:ORPHA846" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004848824" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely Pathogenic</GermlineClassification>
          <Comment>The p.Asn79LysfsX6 variant in HBA1 has been reported in at least 1 individual with alpha thalasemia (Eng 2006 PMID: 16798638). This variant has been reported in ClinVar (Variation ID 619842) and was identified in 11/40942 African chromosomes by gnomAD (https://gnomad.broadinstitute.org). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 79 and leads to a premature termination codon 6 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the HBA1 gene is an established disease mechanism in autosomal recessive Alpha Thalassaemia. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal recessive alpha thalassemia. ACMG/AMP Criteria applied: PVS1, PM2_supporting. (This variant did not meet the variant calling quality criteria, and was included because it has been previously reported as a clinically significant variant.)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000558.5:exon 2</GeneLocation>
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.10:g.177070delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA846" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14389831</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="37510" TraitType="Disease" MappingType="Name" MappingValue="ALPHA-THALASSEMIA" MappingRef="Preferred">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9056506" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA846" MappingRef="Orphanet">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5437908" TraitType="Disease" MappingType="XRef" MappingValue="604131" MappingRef="OMIM">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1739229" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8352566" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5437908" TraitType="Disease" MappingType="XRef" MappingValue="140700" MappingRef="OMIM">
        <MedGen CUI="C0700299" Name="Heinz body anemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7698665" TraitType="Disease" MappingType="Name" MappingValue="HBA1-related condition" MappingRef="Preferred">
        <MedGen CUI="None" Name="HBA1-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5437908" TraitType="Disease" MappingType="XRef" MappingValue="613978" MappingRef="OMIM">
        <MedGen CUI="C3161174" Name="Hemoglobin H disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3921846" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5437908" TraitType="Disease" MappingType="XRef" MappingValue="617981" MappingRef="OMIM">
        <MedGen CUI="C4693823" Name="Erythrocytosis, familial, 7" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5437908" TraitType="Disease" MappingType="XRef" MappingValue="617973" MappingRef="OMIM">
        <MedGen CUI="C4693798" Name="Methemoglobinemia, alpha type" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

